BeiGene To Trade Beach For Chalet In Swiss Redomiciling As BeOne

The biotech saw a slight quarter-over-quarter decline in sales from the BTK inhibitor Brukinsa, which it attributed to seasonality, while revenues overall missed some analyst estimates.